Cargando…

Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon

BACKGROUND: The COVID‐19 pandemic has caused a public health emergency in all sectors of society, including universities and other academic institutions in Cameroon. However, little is known concerning the real prevalence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Essomba, René Ghislain, Bayibeki, Albert Ngano, Lissom, Abel, Ateba, Pulchérie Thérèse, Seni, Nassif, Fouda, Claude Ariane Nlozoa, Mbitock, Solange Berthe Diwandja, Ebonda, Normand David, Afana, Sylvie Delphine, Akame, Siméon, Tembu, Adelphe Anyang, Ngamaleu, Modeste Romuald, Bimai, Bernard Christel Bihonba, Kabo, Ousmane, Nguwoh, Philipe Salomon, Ngounouh, Christian Taheu, Meka, Moise Christian Junior, Kengne, Michel, Likeng, Julienne‐Louise Ngo, Kimessoukie, Etienne Omolomo, Nkoum, Benjamin Alexandre, Assoumou, Marie Claire Okomo, Fokam, Joseph, Yap Boum, I. I., Ambomo, Myriam Sylvie, Chadou, Michael Junior Piameu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640965/
https://www.ncbi.nlm.nih.gov/pubmed/37964992
http://dx.doi.org/10.1111/irv.13222
_version_ 1785146670146650112
author Essomba, René Ghislain
Bayibeki, Albert Ngano
Lissom, Abel
Ateba, Pulchérie Thérèse
Seni, Nassif
Fouda, Claude Ariane Nlozoa
Mbitock, Solange Berthe Diwandja
Ebonda, Normand David
Afana, Sylvie Delphine
Akame, Siméon
Tembu, Adelphe Anyang
Ngamaleu, Modeste Romuald
Bimai, Bernard Christel Bihonba
Kabo, Ousmane
Nguwoh, Philipe Salomon
Ngounouh, Christian Taheu
Meka, Moise Christian Junior
Kengne, Michel
Likeng, Julienne‐Louise Ngo
Kimessoukie, Etienne Omolomo
Nkoum, Benjamin Alexandre
Assoumou, Marie Claire Okomo
Fokam, Joseph
Yap Boum, I. I.
Ambomo, Myriam Sylvie
Chadou, Michael Junior Piameu
author_facet Essomba, René Ghislain
Bayibeki, Albert Ngano
Lissom, Abel
Ateba, Pulchérie Thérèse
Seni, Nassif
Fouda, Claude Ariane Nlozoa
Mbitock, Solange Berthe Diwandja
Ebonda, Normand David
Afana, Sylvie Delphine
Akame, Siméon
Tembu, Adelphe Anyang
Ngamaleu, Modeste Romuald
Bimai, Bernard Christel Bihonba
Kabo, Ousmane
Nguwoh, Philipe Salomon
Ngounouh, Christian Taheu
Meka, Moise Christian Junior
Kengne, Michel
Likeng, Julienne‐Louise Ngo
Kimessoukie, Etienne Omolomo
Nkoum, Benjamin Alexandre
Assoumou, Marie Claire Okomo
Fokam, Joseph
Yap Boum, I. I.
Ambomo, Myriam Sylvie
Chadou, Michael Junior Piameu
author_sort Essomba, René Ghislain
collection PubMed
description BACKGROUND: The COVID‐19 pandemic has caused a public health emergency in all sectors of society, including universities and other academic institutions in Cameroon. However, little is known concerning the real prevalence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections among student communities during the second wave of infection in Cameroon. This study aimed to estimate SARS‐CoV‐2 antibodies seroprevalence among participants in a university community in Cameroon. METHODOLOGY: A cross‐sectional study was conducted from March to April 2021 in 547 students aged ≥18 years during a mass diagnostic campaign at the School of Health Sciences of the Catholic University of Central Africa (ESS/UCAC). The anti‐SARS‐CoV‐2 antibody screening was done using the Panbio™ COVID‐19 IgG/IgM Rapid Diagnostic Test. RESULTS: The overall seroprevalence of SARS‐CoV‐2 antibodies was 27%, of which 89.9% (n = 133) was IgG, 6.7% (n = 10) IgM and 3.4% (n = 5) IgG/IgM positive. The undergraduate students represented 79% (432/547) of the total population and were highly positive with anti‐SARS‐CoV‐2 antibodies 30% (130/432) as compared with postgraduate students 20% (23/115). The total antibody seropositivity was higher in males (34.4%) than females (24.9%). Several factors were associated with an increased risk of SARS‐CoV‐2 seroprevalence including the male gender (OR: 1.61 [95% confidence interval, CI 1.0–2.4]), specialization to medical laboratory (OR: 2.8 [95% CI 1.1–7.1]) and nursing sciences (OR: 2.6 [95% CI 1.1–6.2]). CONCLUSION: Our findings point to extensive and underreported circulation of SARS‐CoV‐2 in a university community during the second wave of infection in Cameroon, which likely resulted in artificially low case counts.
format Online
Article
Text
id pubmed-10640965
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106409652023-11-14 Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon Essomba, René Ghislain Bayibeki, Albert Ngano Lissom, Abel Ateba, Pulchérie Thérèse Seni, Nassif Fouda, Claude Ariane Nlozoa Mbitock, Solange Berthe Diwandja Ebonda, Normand David Afana, Sylvie Delphine Akame, Siméon Tembu, Adelphe Anyang Ngamaleu, Modeste Romuald Bimai, Bernard Christel Bihonba Kabo, Ousmane Nguwoh, Philipe Salomon Ngounouh, Christian Taheu Meka, Moise Christian Junior Kengne, Michel Likeng, Julienne‐Louise Ngo Kimessoukie, Etienne Omolomo Nkoum, Benjamin Alexandre Assoumou, Marie Claire Okomo Fokam, Joseph Yap Boum, I. I. Ambomo, Myriam Sylvie Chadou, Michael Junior Piameu Influenza Other Respir Viruses Original Articles BACKGROUND: The COVID‐19 pandemic has caused a public health emergency in all sectors of society, including universities and other academic institutions in Cameroon. However, little is known concerning the real prevalence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections among student communities during the second wave of infection in Cameroon. This study aimed to estimate SARS‐CoV‐2 antibodies seroprevalence among participants in a university community in Cameroon. METHODOLOGY: A cross‐sectional study was conducted from March to April 2021 in 547 students aged ≥18 years during a mass diagnostic campaign at the School of Health Sciences of the Catholic University of Central Africa (ESS/UCAC). The anti‐SARS‐CoV‐2 antibody screening was done using the Panbio™ COVID‐19 IgG/IgM Rapid Diagnostic Test. RESULTS: The overall seroprevalence of SARS‐CoV‐2 antibodies was 27%, of which 89.9% (n = 133) was IgG, 6.7% (n = 10) IgM and 3.4% (n = 5) IgG/IgM positive. The undergraduate students represented 79% (432/547) of the total population and were highly positive with anti‐SARS‐CoV‐2 antibodies 30% (130/432) as compared with postgraduate students 20% (23/115). The total antibody seropositivity was higher in males (34.4%) than females (24.9%). Several factors were associated with an increased risk of SARS‐CoV‐2 seroprevalence including the male gender (OR: 1.61 [95% confidence interval, CI 1.0–2.4]), specialization to medical laboratory (OR: 2.8 [95% CI 1.1–7.1]) and nursing sciences (OR: 2.6 [95% CI 1.1–6.2]). CONCLUSION: Our findings point to extensive and underreported circulation of SARS‐CoV‐2 in a university community during the second wave of infection in Cameroon, which likely resulted in artificially low case counts. John Wiley and Sons Inc. 2023-11-12 /pmc/articles/PMC10640965/ /pubmed/37964992 http://dx.doi.org/10.1111/irv.13222 Text en © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Essomba, René Ghislain
Bayibeki, Albert Ngano
Lissom, Abel
Ateba, Pulchérie Thérèse
Seni, Nassif
Fouda, Claude Ariane Nlozoa
Mbitock, Solange Berthe Diwandja
Ebonda, Normand David
Afana, Sylvie Delphine
Akame, Siméon
Tembu, Adelphe Anyang
Ngamaleu, Modeste Romuald
Bimai, Bernard Christel Bihonba
Kabo, Ousmane
Nguwoh, Philipe Salomon
Ngounouh, Christian Taheu
Meka, Moise Christian Junior
Kengne, Michel
Likeng, Julienne‐Louise Ngo
Kimessoukie, Etienne Omolomo
Nkoum, Benjamin Alexandre
Assoumou, Marie Claire Okomo
Fokam, Joseph
Yap Boum, I. I.
Ambomo, Myriam Sylvie
Chadou, Michael Junior Piameu
Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon
title Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon
title_full Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon
title_fullStr Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon
title_full_unstemmed Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon
title_short Seroprevalence of SARS‐CoV‐2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon
title_sort seroprevalence of sars‐cov‐2 antibodies and associated risk factors during the second wave of infection in a university community in cameroon
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640965/
https://www.ncbi.nlm.nih.gov/pubmed/37964992
http://dx.doi.org/10.1111/irv.13222
work_keys_str_mv AT essombareneghislain seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT bayibekialbertngano seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT lissomabel seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT atebapulcherietherese seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT seninassif seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT foudaclaudearianenlozoa seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT mbitocksolangeberthediwandja seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT ebondanormanddavid seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT afanasylviedelphine seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT akamesimeon seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT tembuadelpheanyang seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT ngamaleumodesteromuald seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT bimaibernardchristelbihonba seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT kaboousmane seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT nguwohphilipesalomon seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT ngounouhchristiantaheu seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT mekamoisechristianjunior seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT kengnemichel seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT likengjuliennelouisengo seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT kimessoukieetienneomolomo seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT nkoumbenjaminalexandre seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT assoumoumarieclaireokomo seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT fokamjoseph seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT yapboumii seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT ambomomyriamsylvie seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon
AT chadoumichaeljuniorpiameu seroprevalenceofsarscov2antibodiesandassociatedriskfactorsduringthesecondwaveofinfectioninauniversitycommunityincameroon